<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e455/7698872/ef17b637c009/ijms-21-08721-g006.jpg"/> </div> <div class="text-side"> <h1>Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.</h1> <p>H&amp;E staining and IHC staining of tumors. Panel (a): First row, H&amp;E staining of tumors from cold h8C3, ICB, and RIT 177Lu (low) + ICB treatment groups. Second row, anti-CD3 IHC staining under 400X magnification; brown staining surrounds the nuclear indicate the CD3+ cells. Bottom row, anti-Ki67 IHC staining under 100X magnification, and brown staining overlaps with the nuclear indicate the Ki67+ cells. Panel (b): upper row—number of CD3-positive cells in cold h8C3, ICB, and RIT + ICB treatment group; lower row—number of Ki67-positive cells in cold h8C3, ICB, and RIT + ICB treatment group.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33218169/" target="_blank">33218169</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>